ARS Pharmaceuticals (SPRY) Leases (2021 - 2025)
Historic Leases for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to $1.4 million.
- ARS Pharmaceuticals' Leases rose 146413.04% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 146413.04%. This contributed to the annual value of $37000.0 for FY2024, which is 8520.0% down from last year.
- Per ARS Pharmaceuticals' latest filing, its Leases stood at $1.4 million for Q3 2025, which was up 146413.04% from $1.6 million recorded in Q2 2025.
- In the past 5 years, ARS Pharmaceuticals' Leases registered a high of $5.0 million during Q3 2021, and its lowest value of $37000.0 during Q4 2024.
- Its 5-year average for Leases is $1.3 million, with a median of $421500.0 in 2022.
- As far as peak fluctuations go, ARS Pharmaceuticals' Leases crashed by 9112.4% in 2023, and later surged by 146413.04% in 2025.
- ARS Pharmaceuticals' Leases (Quarter) stood at $621000.0 in 2021, then dropped by 28.34% to $445000.0 in 2022, then plummeted by 43.82% to $250000.0 in 2023, then tumbled by 85.2% to $37000.0 in 2024, then skyrocketed by 3789.19% to $1.4 million in 2025.
- Its Leases stands at $1.4 million for Q3 2025, versus $1.6 million for Q2 2025 and $72000.0 for Q1 2025.